How this receipt has changed
The Food and Drug Administration requires a Risk Evaluation and Mitigation Strategy for opioid analgesic products to ensure benefits outweigh the risks of addiction, abuse, and misuse.
This receipt has not been rewritten since it was published on 04 Oct 2026. Its current version is 1.
Weight is the one the receipt's balance bar uses: every source counts 1, plus a bounded bonus for how often it has been cited, so one famous paper cannot outweigh three dissenting ones (at most 3x a bare source). It is a reading aid built from facts the receipt already stores, not the engine's confidence.
The same numbers as a table
| Version | Verdict | For | Against | Weight for | Weight against | From |
|---|---|---|---|---|---|---|
| v1 | SUPPORTED | 3 | 0 | 3.1 | 0 | 2026-10-04 |
Every version
- Version 1 (current)in effect since 04 Oct 2026SUPPORTED3 for, 0 against · confidence 81